Cellectar Biosciences, Inc. (CLRB)

The investment case here is fundamentally broken despite the recent headlines of a massive financing round and a cancer trial spark. While the company successfully raised $140 million, which temporarily staved off the bleeding, the underlying business has suffered a catastrophic collapse in value over the last decade, dropping nearly 99.9% from its peak. The market has spoken clearly: the asset is trading at less than 80 cents on the dollar relative to its book value, yet it is burning through cash at a rate that requires constant capital raises just to survive. There is no dividend to provide income, and the recent price action shows no recovery, hovering near multi-year lows. The 'strong buy' analyst ratings appear to be based on a binary view of survival rather than a realistic assessment of the deteriorating fundamentals and the immense execution risk inherent in late-stage biotech development. Until there is concrete proof of a product launch or significant revenue generation, this remains a speculative gamble on a turnaround that the market has largely priced out.